Structure Therapeutics Inc. announced the appointment of Matthew Lang, J.D. as Chief Operating Officer and General Counsel, effective April 15, 2026. Mr. Lang joins Structure Therapeutics with more than fifteen years of executive leadership experience across global biopharmaceutical organizations, with deep expertise spanning legal, corporate strategy, compliance, risk management, and business development. Mr. Lang previously served as the Chief Legal Officer and Corporate Secretary at Metsera Inc. (Metsera), a biopharmaceutical company, from April 2025 until February 2026 and prior to Metsera Mr. Lang served as Chief Business Officer and Chief Legal Officer and Corporate Secretary of Lyell Immunopharma Inc. (Lyell), a biotechnology company, from July 2023 to April 2025.
Before joining Lyell, Mr. Lang held several executive officer positions at Myovant Sciences Inc. (Myovant), a biotechnology company, between 2017 and 2023, most recently as Chief Administrative and Legal Officer. Mr. Lang also served as Managing Director and General Manager of Myovant Sciences GmbH in Basel, Switzerland. Mr. Lang previously held leadership positions at Gilead Sciences Inc. (Gilead), from November 2009 to July 2017, most recently as Vice President, Head of Global Litigation, Investigations, Employment Law and Information Governance.
Prior to Gilead, from 2003 to 2009, Mr. Lang was an attorney at Dechert LLP. Mr. Lang received his B.A. in Classical Studies from Queen?s University at Kingston, Canada and his J.D. from the University of Pennsylvania Law School.
